← All organizations
Highest phase reached
Phase 3
First clinical trial
Jan 1, 2007First marketed drug
Mar 18, 2022First NDA
Mar 18, 2022Last known activity
Sep 30, 2023
Timeline
2000s
- Jun 1, 2003
Marinus Pharmaceuticals— Founded
2020s
- Mar 18, 2022
ganaxolone— Marketing Organization
- Mar 18, 2022
ganaxolone— NDA Organization
- Mar 18, 2022
ganaxolone— NDA Secondary Org
Drugs by trial phase (2 distinct, 23 trials)
Phase 3 (2 own, 0 via acquisition)
Indications
Studied for
- Behavioral Symptoms
- Depression
- Depression, Postpartum
- Depressive Disorder
- Disease
- Epilepsies, Partial
- Epilepsy
- Epilepsy, Complex Partial
- Fragile X Syndrome
- Mental Disorders
- Mood Disorders
- Muscle Cramp
- Pregnancy Complications
- Puerperal Disorders
- Sclerosis
- Seizures
- Spasm
- Spasms, Infantile
- Status Epilepticus
- Stress Disorders, Post-Traumatic
- Stress Disorders, Traumatic
- Syndrome
- Tuberous Sclerosis
Marketed drugs (1)
Recent trials (33)
- NCT04678479Study directorN/A—
- NCT04678479Lead sponsorN/A—
- NCT05814523Lead sponsorPhase 3Sep 30, 2023
- NCT05249556Lead sponsorPhase 3May 31, 2023
- NCT05757544Lead sponsorPhase 2Apr 1, 2023
- NCT05604170Lead sponsorPhase 3May 16, 2022
- NCT05323734Lead sponsorPhase 3Apr 1, 2022
- NCT04391569Study directorPhase 3Aug 31, 2020
- NCT04391569Lead sponsorPhase 3Aug 31, 2020
- NCT04285346Study directorPhase 2Apr 30, 2020
- NCT04285346Lead sponsorPhase 2Apr 30, 2020
- NCT03865732Study directorPhase 3May 31, 2019
- NCT03865732Lead sponsorPhase 3May 31, 2019
- NCT03572933Study directorPhase 3Jun 30, 2018
- NCT03572933Lead sponsorPhase 3Jun 30, 2018
Details
- Founded
- Branford, CT, US Jun 1, 2003
- First NDA
- Mar 18, 2022
- Last known activity
- Sep 30, 2023
Designations held
- Orphan drug
- Priority review